Citations 2
Atrioventricular Node Ablation for Atrial Fibrillation in a Patient With EVOQUE Tricuspid Valve: A First Reported Case
Muthu, Padmapriya , Vemulapalli, Hema Srikanth , Prajapati, Poojan , Rodriguez, Juan F. , Lone, Ahmad Naeem, Srivathsan, Komandoor , Vemulapalli, Hema S , Rodriguez-Riascos, Juan F , Srivathsan, Komandoor , Muthu, Padmapriya
Journal of Cardiovascular Electrophysiology | March 11, 2025 | Volume: 36 | Issue: 5 | Pages: 1107-1111
ABSTRACT Introduction Atrial fibrillation (AF) is the most common arrhythmia, and atrioventricular (AV) node ablation with pacemaker implantation is a therapeutic option for refractory cases. However, AV node ablation in patients with bioprosthetic tricuspid valves poses technical challenges. Methods An 84‐year‐old male with an EVOQUE transcatheter tricuspid valve replacement underwent AV node ablation (AVNA) under intracardiac echocardiography (ICE) guidance. Results Successful AV block was achieved with precise catheter positioning, improving the patient's symptoms and ventricular rate control. Conclusion This case demonstrates the feasibility of AVNA in patients with tricuspid bioprostheses, demonstrating feasibility with ICE guidance.
Atrioventricular Node Ablation for Atrial Fibrillation in a Patient with EVOQUE Tricuspid Valve: A First Reported Case
Muthu, Padmapriya , Prajapati, Poojan , Rodriguez, Juan F. , Lone, Ahmad Naeem, Rodriguez-Riascos, Juan F , Muthu, Padmapriya , Vemulapalli, Hema Srikanth , Srivathsan, Komandoor
No container title available | January 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available
10.22541/au.173763833.36784520/v1
This is the first reported case of atrioventricular node ablation (AVNA) in a patient with an EVOQUE transcatheter tricuspid valve, performed for refractory atrial fibrillation with uncontrolled ventricular rates. This case highlights the feasibility and importance of advanced imaging techniques in managing arrhythmias in patients with bioprosthetic valves, offering insights into expanding therapeutic options for complex cardiovascular conditions.